SCHEMBL28030062

SCHEMBL28030062

O=C(O)c1ccc(N2CCN(C(=O)O)CC2)cc1Oc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.55
▸ TSHR P16473 4/20 0.55
▸ MAPT P10636 3/20 0.55
▸ MEN1 O00255 3/20 0.55
▸ KMT2A Q03164 3/20 0.55
▸ LMNA P02545 1/20 0.55
▸ TP53 P04637 1/20 0.55
▸ HSD17B10 Q99714 1/20 0.55
▸ HTR6 P50406 1/20 0.47
▸ HCAR2 Q8TDS4 1/20 0.46
▸ CRHBP P24387 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ CRHR2 Q13324 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ TRPC6 Q9Y210 1/20 0.43
▸ FAAH O00519 1/20 0.43
▸ ME2 P23368 1/20 0.42
▸ ME1 P48163 1/20 0.42
▸ ME3 Q16798 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27910608 0.88 MAPT (0.51) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL1955785 0.85 PDK2 (0.51) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL28103092 0.84 LTA4H (0.58) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL27906257 0.75 LMNA (0.49) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL1955303 0.75 PDK2 (0.51) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL5236570 0.75 ALDH1A1 (0.64) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL1742180 0.73 BCL2 (0.63) —
SCHEMBL1957162 0.73 CYP2C9 (0.47) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL1955377 0.73 LTA4H (0.53) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL18300991 0.72 MAPT (0.52) ALDH1A1TSHRMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102947285-B Sulfonamide derivatives as BCL-2-selective apoptosis inducers for the treatment of cancer and immune diseases ABBVIE (US) 2015-08-26 — — CN disclosed
Send feedback